Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesScopus Biopharma Inc

Scopus Biopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0004 USD 0.00(0%)
Last update at 2026-11-10T21:00:00Z
VOLUME
47076
Market Cap
0.03M

Momentum Score

…

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Scopus Biopharma Inc is an OTC-listed biotechnology company; public filings are limited and its product pipeline and commercialization status are not fully detailed. Long-term growth may depend on clinical and regulatory progress, strategic partnerships and access to development capital, which could support value creation if programs advance.

Key risks include limited public disclosure and low trading liquidity, plus typical biotech exposures to clinical or regulatory failure, financing requirements and potential equity dilution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-1.25
ROE
-1559.60%
Net Debt
-0.12M
ROCE
165.88%
Diluted EPS TTM
-0.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -11.71M -26.95M -10.86M -2.69M -0.69M
Minority interest 0.11M - - - -
Net income -11.61M -25.50M -11.57M -2.69M -0.69M
Selling general administrative 9.03M 12.61M 2.73M 2.23M 0.41M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M -
Ebit -11.71M -27.63M -10.16M -2.69M -0.69M
Ebitda -11.71M -27.63M -10.15M -2.69M -0.69M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M -
Operating income -11.71M -27.63M -10.16M -2.69M -0.69M
Other operating expenses 11.71M 27.63M 10.16M 2.69M 0.69M
Interest expense 0.00M 0.77M 0.71M 0.00M 0.00M
Net interest income 0.00M -0.77M -0.71M - -
Income tax expense -0.11M -1.46M 0.71M 0.00M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 11.71M 27.63M 10.16M 2.69M 0.69M
Total other income expense net - 0.68M -0.71M -2.69M -0.69M
Net income from continuing ops -11.71M -26.95M -10.86M -2.69M -0.69M
Net income applicable to common shares -11.61M -26.95M -10.86M -2.69M -0.69M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 0.39M 8.19M 1.97M 0.77M 0.13M
Other current assets 0.27M 0.24M 0.14M 0.00M 0.10M
Total liab 7.45M 4.17M 3.81M 0.85M 0.14M
Total stockholder equity -6.56M 4.02M -1.83M -0.08M -0.01M
Other current liab 7.45M 4.17M 1.52M 0.85M 0.14M
Common stock 0.02M 0.02M 0.01M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.01M 0.01M 0.01M
Retained earnings -53.06M -41.46M -14.50M -3.64M -0.95M
Cash 0.12M 7.94M 1.83M 0.04M 0.00M
Total current liabilities 7.45M 4.17M 3.81M 0.85M 0.14M
Net debt -0.12M -7.94M 0.45M -0.04M -0.00M
Short term debt - - 2.28M - -
Short long term debt - - 2.28M - -
Short long term debt total - - 2.28M - -
Other stockholder equity 46.48M 45.54M 12.72M 3.58M 0.94M
Property plant equipment 0.00M 0.00M 0.00M 0.00M -
Total current assets 0.39M 8.18M 1.97M 0.77M 0.13M
Net tangible assets -6.56M 4.02M -1.83M -0.08M -0.01M
Net receivables - - - 0.00M 0.03M
Inventory - - - 0.73M -
Accounts payable 0.18M 0.12M 1.52M 0.16M -
Accumulated other comprehensive income -0.00M -0.09M -0.07M -0.03M -0.01M
Common stock total equity - - 0.01M 0.01M 0.01M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.00M -0.00M 0.00M -0.00M -
Change to liabilities 3.01M 2.94M 1.18M 0.32M 0.00M
Total cashflows from investing activities -0.00M -0.00M -0.00M -0.00M -0.00M
Net borrowings - -0.10M 2.19M 2.19M 2.19M
Total cash from financing activities 0.24M 17.56M 4.35M 2.18M 0.60M
Change to operating activities 0.23M -0.10M -0.04M 0.04M -0.13M
Net income -11.71M -26.95M -10.86M -2.69M -0.69M
Change in cash -7.82M 6.11M 1.80M 0.04M -0.16M
Begin period cash flow 7.94M 1.83M 0.04M 0.00M 0.16M
End period cash flow 0.12M 7.94M 1.83M 0.04M 0.00M
Total cash from operating activities -8.13M -11.42M -2.53M -2.12M -0.75M
Issuance of capital stock 0.00M 20.10M 3.27M 1.78M 0.54M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Other cashflows from financing activities 0.24M -2.44M 1.08M 0.41M 0.06M
Change to netincome 0.25M 12.69M 6.64M 0.21M 0.07M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 3.23M 2.84M 1.15M 0.36M -0.13M
Stock based compensation 0.35M 0.67M 0.27M 0.12M 0.07M
Other non cash items - 12.02M 6.92M 0.09M -
Free cash flow -8.13M -11.43M -2.53M -2.12M -0.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
SCPS
Scopus Biopharma Inc		 -
-%		 0.00 - - - 2.42 0.12
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Scopus Biopharma Inc

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.

420 Lexington Avenue, New York, NY, United States, 10170

212 479 2513

https://scopusbiopharma.com

13

Name Title Year Born
Mr. Robert J. Gibson Vice Chairman, Sec. & Treasurer NA
Mr. Ira Scott Greenspan Sr. Advisor & Director 1959
Mr. David Silberg Sr. Advisor 1949
Dr. Alan D. Horsager Ph.D. Pres?of?Immuno-Oncology and Pres & CEO of Duet BioTherapeutics 1973
Mr. Ira Scott Greenspan Senior Advisor & Director 1959
Mr. Robert J. Gibson Vice Chairman, Secretary & Treasurer NA
Dr. Alan D. Horsager Ph.D. President?of?Immuno-Oncology and President & CEO of Duet BioTherapeutics 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 106.39
+7.88%
GRZ
CAD 4.80
+5.26%
CTC
CAD 226.00
+4.63%
CAE
CAD 40.63
+4.21%
FEC
CAD 7.26
+3.57%
FSZ
CAD 2.40
-15.79%
TF
CAD 4.56
-11.28%
ITR
CAD 2.71
-9.67%
LAR
CAD 5.23
-7.43%
BZ
CAD 4.00
-7.41%

Equity Sectors*

  • Basic Materials

    -2.89%

  • Communication Services

    +0.25%

  • Consumer Cyclical

    +0.37%

  • Consumer Defensive

    -0.02%

  • Energy

    -0.30%

  • Financial Services

    -1.06%

  • Healthcare

    -0.73%

  • Industrials

    -0.49%

  • Real Estate

    +0.22%

  • Technology

    -1.52%

  • Utilities

    +0.08%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…